CA2409930C - Use of zoledronate for the manufacture of a medicament for the treatment of bone metabolism diseases - Google Patents
Use of zoledronate for the manufacture of a medicament for the treatment of bone metabolism diseases Download PDFInfo
- Publication number
- CA2409930C CA2409930C CA2409930A CA2409930A CA2409930C CA 2409930 C CA2409930 C CA 2409930C CA 2409930 A CA2409930 A CA 2409930A CA 2409930 A CA2409930 A CA 2409930A CA 2409930 C CA2409930 C CA 2409930C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- treatment
- imidazol
- hydroxyethane
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 238000011282 treatment Methods 0.000 title claims abstract description 60
- 239000003814 drug Substances 0.000 title claims description 14
- 208000018083 Bone metabolism disease Diseases 0.000 title claims description 10
- 229960004276 zoledronic acid Drugs 0.000 title description 50
- 238000004519 manufacturing process Methods 0.000 title description 2
- 150000003839 salts Chemical class 0.000 claims abstract description 49
- 229940122361 Bisphosphonate Drugs 0.000 claims abstract description 26
- 150000004663 bisphosphonates Chemical class 0.000 claims abstract description 23
- 238000001990 intravenous administration Methods 0.000 claims description 43
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 238000001802 infusion Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 13
- 208000034578 Multiple myelomas Diseases 0.000 claims description 11
- 210000000988 bone and bone Anatomy 0.000 claims description 11
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 10
- 206010027476 Metastases Diseases 0.000 claims description 10
- 230000000148 hypercalcaemia Effects 0.000 claims description 10
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 8
- 230000009401 metastasis Effects 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 239000003978 infusion fluid Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 14
- 239000002253 acid Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 15
- 206010060862 Prostate cancer Diseases 0.000 description 10
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 206010027452 Metastases to bone Diseases 0.000 description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 9
- 229940046231 pamidronate Drugs 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- -1 bisphosphonate compound Chemical class 0.000 description 5
- 239000006172 buffering agent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 5
- 229940038773 trisodium citrate Drugs 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001582 osteoblastic effect Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000121 hypercalcemic effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000037099 Prosthesis Failure Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000123 anti-resoprtive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000011240 pooled analysis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- JBJWASZNUJCEKT-UHFFFAOYSA-M sodium;hydroxide;hydrate Chemical compound O.[OH-].[Na+] JBJWASZNUJCEKT-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0012209.3A GB0012209D0 (en) | 2000-05-19 | 2000-05-19 | Organic compounds |
| GB0012209.3 | 2000-05-19 | ||
| PCT/US2001/014886 WO2001089494A2 (en) | 2000-05-19 | 2001-05-09 | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2409930A1 CA2409930A1 (en) | 2001-11-29 |
| CA2409930C true CA2409930C (en) | 2012-08-28 |
Family
ID=9891987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2409930A Expired - Fee Related CA2409930C (en) | 2000-05-19 | 2001-05-09 | Use of zoledronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1286665B1 (enExample) |
| JP (3) | JP2004501104A (enExample) |
| CN (1) | CN100389772C (enExample) |
| AU (2) | AU2001261283B2 (enExample) |
| BR (1) | BR0110913A (enExample) |
| CA (1) | CA2409930C (enExample) |
| ES (1) | ES2409033T3 (enExample) |
| GB (1) | GB0012209D0 (enExample) |
| WO (1) | WO2001089494A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014724A1 (en) | 2001-05-09 | 2004-01-22 | Seaman John J. | Method of administering a bisphosphonate |
| DK1296689T3 (da) | 2000-06-20 | 2005-11-28 | Novartis Ag | Fremgangsmåde til indgivelse af bisphosphonater |
| BR0308901A (pt) | 2002-05-10 | 2005-01-04 | Hoffmann La Roche | ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose |
| TWI344367B (en) * | 2002-09-16 | 2011-07-01 | Novartis Ag | Use of zoledronic acid or a pharmaceutically acceptable salt or hydrate thereof in the preparation of a medicament for the treatment of osteoporosis post hip fracture |
| ES2530791T3 (es) | 2002-12-20 | 2015-03-05 | Hoffmann La Roche | Formulación de ibandronato de altas dosis |
| MY141763A (en) * | 2003-09-18 | 2010-06-30 | Novartis Ag | Pharmaceutical products comprising bisphosphonates |
| WO2006062876A2 (en) | 2004-12-09 | 2006-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
| DK1930414T3 (da) * | 2005-09-08 | 2012-10-22 | Medinet Co Ltd | Fremgangsmåde til aktiveringsbehandling af antigenpræsenterende celle |
| JP5829400B2 (ja) * | 2008-01-24 | 2015-12-09 | レメドー バイオメッド リミテッド | 骨再生のためのエリスロポイエチンおよびフィブロネクチン組成物 |
| DK2473172T3 (en) | 2009-09-01 | 2015-06-15 | Univ Duke | BISPHOSPHONATSAMMENSÆTNINGER and Methods for treating congestive heart failure |
| CN102000035B (zh) * | 2010-10-13 | 2012-07-25 | 江苏奥赛康药业股份有限公司 | 一种供注射用的唑来膦酸组合物及其制备方法 |
| WO2013074587A1 (en) | 2011-11-16 | 2013-05-23 | Duke University | Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction |
| RU2519120C1 (ru) * | 2012-11-06 | 2014-06-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ профилактики скелетных осложнений у больных с литическими метастазами в плоские и смешанные кости |
| DE102014004512A1 (de) * | 2014-03-28 | 2015-10-01 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin | Anorganisch-organische Hybridverbindung |
| BE1021270B1 (nl) * | 2014-06-17 | 2015-10-14 | Neogen N.V. | Zoledronine oplossing |
| CN105213407B (zh) * | 2015-07-01 | 2018-01-02 | 南京大学 | 唑来膦酸用于制备治疗脂肪性肝病的药物的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014724A1 (en) | 2001-05-09 | 2004-01-22 | Seaman John J. | Method of administering a bisphosphonate |
-
2000
- 2000-05-19 GB GBGB0012209.3A patent/GB0012209D0/en not_active Ceased
-
2001
- 2001-05-09 AU AU2001261283A patent/AU2001261283B2/en not_active Expired
- 2001-05-09 BR BR0110913-8A patent/BR0110913A/pt not_active Application Discontinuation
- 2001-05-09 JP JP2001585739A patent/JP2004501104A/ja not_active Withdrawn
- 2001-05-09 ES ES01935167T patent/ES2409033T3/es not_active Expired - Lifetime
- 2001-05-09 WO PCT/US2001/014886 patent/WO2001089494A2/en not_active Ceased
- 2001-05-09 EP EP01935167.5A patent/EP1286665B1/en not_active Revoked
- 2001-05-09 AU AU6128301A patent/AU6128301A/xx active Pending
- 2001-05-09 CN CNB018097812A patent/CN100389772C/zh not_active Ceased
- 2001-05-09 CA CA2409930A patent/CA2409930C/en not_active Expired - Fee Related
-
2012
- 2012-03-09 JP JP2012053573A patent/JP2012162531A/ja not_active Withdrawn
-
2013
- 2013-04-17 JP JP2013086245A patent/JP2013151553A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2409033T3 (es) | 2013-06-24 |
| JP2004501104A (ja) | 2004-01-15 |
| JP2012162531A (ja) | 2012-08-30 |
| EP1286665B1 (en) | 2013-04-17 |
| WO2001089494A2 (en) | 2001-11-29 |
| EP1286665A2 (en) | 2003-03-05 |
| WO2001089494A8 (en) | 2003-04-17 |
| GB0012209D0 (en) | 2000-07-12 |
| CA2409930A1 (en) | 2001-11-29 |
| WO2001089494A3 (en) | 2002-05-23 |
| BR0110913A (pt) | 2003-12-30 |
| AU6128301A (en) | 2001-12-03 |
| CN100389772C (zh) | 2008-05-28 |
| CN1481247A (zh) | 2004-03-10 |
| AU2001261283B2 (en) | 2005-01-13 |
| JP2013151553A (ja) | 2013-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012162531A (ja) | 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用 | |
| RU2238736C2 (ru) | Фармацевтическая парентеральная композиция, содержащая бифосфонат | |
| ES2287191T3 (es) | Uso de acido zoledronico para el tratamiento del dolor. | |
| AU2001261283A1 (en) | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | |
| AU2002217061A1 (en) | Use of bisphosphonates for pain treatment | |
| US8324189B2 (en) | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | |
| EP1166773A1 (en) | Solution of N- O(p-pivaloyloxbenzenesulfonylamino)benzoyl glycine monosodium salt tetra-hydrate and drug product thereof | |
| AU2001277115A1 (en) | Use of estramustine phosphate in the treatment of bone metastasis | |
| US20040014729A1 (en) | Use of estramustine phosphate in the treatment of bone metastasis | |
| CA2183764C (en) | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration | |
| HK1055901A (en) | Use of estramustine phosphate in the treatment of bone metastasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160509 |